PF317 ELEVATION OF SERUM IL‐10 IS ASSOCIATED WITH ADVERSE CLINICAL OUTCOMES IN PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA WHO WERE TREATED WITH R‐CHOP

Abstract

Background:Cytokines are one of the major non‐cellular component of tumor microenvironment, and they act as messengers between malignant cells and the cellular component of tumor microenvironment to promote cancer cell proliferation and to evade immune surveillance. While the role of cytokine had been widely investigated in patients with DLBLC, their impacts on secondary CNS involvement had rarely been reported.Aims:To address prognostic roles of serum cytokines regarding the OS and CNS events in DLBCL patients.Methods:Patients out of our prospective cohort study (NCT#00822731) who met the following criteria were included in the present study. 1) Patients with newly diagnosed, histologically confirmed DLBCL, other than primary CNS lymphoma; 2) Patients who were treated with R‐CHOP as the first‐line treatment; 3) Patients whose serum samples were collected. The clinical data of patients were collected. Serum levels of IL‐2, IL‐6, IL‐10, IL‐21, CXCL10, CCL3, CCL5, PAI‐1, survivin, and TNFα were measured. The primary end‐point of the current study was estimated 3‐year overall survival (OS) rate, and the secondary end‐point was time to secondary CNS involvementResults:A total of 313 patients were eligible for the analysis. The median age was 56 years (range, 16 to 86 years) and 177 patients (57%) were male. The 3‐year OS rate was 73.6% ( ± 2.5%), and all the factors in IPI significantly discriminated the OS. Six cytokines were correlated with the 3‐year OS rate (FIGURE). Time to CNS involvement was assess in 294 patients, and 16 events (5.4%) of secondary CNS involvement were detected. Only one cytokine could predict it, as patients with elevated IL‐10 was associated with significantly short time to CNS involvement compared to patients without IL‐10 elevation (p = 0.012). While only 1 out of 99 patients (1.0%) without IL‐10 elevation developed secondary CNS involvement, 15 out of 195 patients (7.7%) with IL‐10 elevation developed secondary CNS involvement (p = 0.017). Of note, among 19 patients who initially had CNS involvement, 14 patients (74%) had elevated serum IL‐10.Summary/Conclusion:We have found that elevation of CCL3, CCL5, CXCL10, IL‐6, IL‐10, and survivin were associated with inferior 3‐year OS rate, and elevation of IL‐10 was associated with short time to secondary CNS involvement. Considering their biologic roles in lymphomagenesis, further studies are required to incorporate these results to conventional prognostic factors to better predict outcomes of patients with DLBCLimage